We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rtw Biotech Opportunities Ltd | LSE:RTWG | London | Ordinary Share | GG00BKTRRM22 | ORD NPV (GBP) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 105.50 | 104.00 | 107.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | 2.17M | -5.29M | -0.0251 | -42.03 | 222.22M |
TIDMRTW
RNS Number : 2631X
RTW Venture Fund Limited
24 April 2023
LEI: 549300Q7EXQQH6KF7Z84
24 April 2023
RTW Venture Fund Limited
March Factsheet & First Quarter Letter
-2.7% NAV Return for the Quarter Ended 31 March 2023
RTW Venture Fund Limited (the "Company"), the London Stock Exchange Premium Listed investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors is pleased to announce that the March Factsheet and First Quarter 2023 Letter are available on the Company's website.
Developments in the quarter:
-- The Russell 2000 Biotech Index (-8.0%) and the Nasdaq Biotech Index (-2.1%) fell over the quarter despite significant M&A in the sector.
-- Cincor was acquired by AstraZeneca for a total deal value of $1.8bn, a 206% premium to the prior closing value.
-- Orchestra BioMed merged with RTW's Health Sciences Acquisitions Corporation and started trading on Nasdaq.
-- Mineralys went public through an upsized IPO and traded well on debut.
-- The Company co-led private financing rounds in two cell therapy companies: Orciell Therapeutics and Cargo Therapeutics.
-- Milestone announced a $125m strategic financing deal with RTW-managed funds include the Company
-- Avidity announced that discussions with the FDA were ongoing regarding the partial clinical hold of it Phase 1/2 clinical trial for AOC1001.
-- After the quarter end, Prometheus Biosciences, the Company's largest position was acquired by Merck for $10.8bn, a 75% premium to the prior closing value.
For Further Information:
RTW Investments, LP +44 (0)20 7959 6361 Woody Stileman, Managing Director Krisha McCune, Director, Client Service Buchanan +44 (0)20 7466 5107 Charles Ryland Henry Wilson George Beale Numis +44 (0)20 7260 1000 Freddie Barnfield Nathan Brown Euan Brown BofA Securities +44 (0) 20 7628 1000 Edward Peel Kieran Millar Elysium Fund Management Limited +44 (0) 14 8181 0100 Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director Morgan Stanley Fund Services USA LLC +1 (914) 225 8885
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCPPUQGCUPWGWC
(END) Dow Jones Newswires
April 24, 2023 09:39 ET (13:39 GMT)
1 Year Rtw Biotech Opportunities Chart |
1 Month Rtw Biotech Opportunities Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions